February 27, 2023Open Access

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer

Key Points

Key points are not available for this paper at this time.

Abstract

Apalutamide plus ADT demonstrated a robust (rapid, deep, and durable) PSA decline that was associated with improved clinical outcomes, including long-term survival.

Bookmark

View Full Paper

Bookmark

View Full Paper

Cite This Study

Chowdhury et al. (Mon,) studied this question.

synapsesocial.com/papers/69dd278bf0cb8f4dd53591f4 https://doi.org/https://doi.org/10.1016/j.annonc.2023.02.009

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC): The ARCHES trial2019 · 2 citations